NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2A Recommendation4,5*
The NCCN Guidelines® for Soft Tissue Sarcoma (STS) recommend olaratumab (LARTRUVO) in combination with doxorubicin for treatment of adult patients with STS.
The NCCN Guidelines for Uterine Neoplasms recommend olaratumab (LARTRUVO) in combination with doxorubicin as a systemic therapy option for the treatment of uterine sarcoma.†
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
*Category 2A recommendation is based on lower-level evidence and there is uniform NCCN consensus that the intervention is appropriate.
†Clinical trials are strongly recommended.
‡The clinical benefits of LARTRUVO for any one histologic subtype of STS have not been established.
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Helpful information for patients to learn what they can expect from treatment with LARTRUVO.
Find easy-to-use forms and reimbursement information to help support your patient's treatment journey.
Lilly PatientOne is committed to helping eligible patients access support programs for Lilly Oncology products they are prescribed. We aim to address both financial and coverage issues for qualified uninsured, underinsured, and insured patients. Lilly PatientOne strives to offer resources, ranging from benefits investigations to financial assistance and appeals information, that provide reliable and individualized treatment support for eligible patients.
- Lilly PatientOne Co-pay Program—patients pay no more than $25 per dose—to assist eligible patients with co-pay and coinsurance costs for prescribed Lilly Oncology products where available*
- No income eligibility requirement
- Provides an annual maximum patient benefit of $25,000
- Billing and coding information
- Payment methodologies and allowables
- Payer policy information
- Eligibility determination
- Benefits investigation
- Prior authorization assistance
- Denied claims appeals information
Lilly Cares Foundation
The Lilly Cares Foundation, Inc., a separate nonprofit organization, provides free Lilly medications to qualifying patients. For more information about Lilly Cares, please visit LillyCares.com or call 1-800-545-6962.
For more information about Lilly PatientOne, call 1-866-4PatOne (1-866-472-8663), Monday–Friday, 9 AM–7 PM ET, or visit LillyPatientOne.com.
Lilly Oncology offers a suite of tools and resources to facilitate treatment with LARTRUVO and help you provide the best possible care for your patients.
Helpful billing and coding information for LARTRUVO.
Helpful information on the specialty distributors and specialty pharmacy that Lilly has contracted to help provide LARTRUVO to customers.
This resource provides suggested guidance on how to populate the CMS-1450 claim form when submitting a claim for the administration of LARTRUVO in the outpatient hospital setting.
This resource provides suggested guidance on how to populate the CMS-1500 claim form when submitting a claim for the administration of LARTRUVO in the physician’s office.
Effective January 1, 2018, the following code can be used for administrative and billing purposes specific to LARTRUVO® (olaratumab): J9285, Injection, olaratumab, 10 mg for physician office use. This information is presented for information purposes only and is not intended to provide reimbursement or legal advice.